Day One Biopharmaceuticals (DAWN) Competitors

$16.17
+0.14 (+0.87%)
(As of 05/17/2024 ET)

DAWN vs. AVDL, DVAX, PCRX, MORF, AKRO, ANIP, KNSA, GMTX, LGND, and GYRE

Should you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Avadel Pharmaceuticals (AVDL), Dynavax Technologies (DVAX), Pacira BioSciences (PCRX), Morphic (MORF), Akero Therapeutics (AKRO), ANI Pharmaceuticals (ANIP), Kiniksa Pharmaceuticals (KNSA), Gemini Therapeutics (GMTX), Ligand Pharmaceuticals (LGND), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical preparations" industry.

Day One Biopharmaceuticals vs.

Avadel Pharmaceuticals (NASDAQ:AVDL) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, community ranking, profitability, risk and earnings.

In the previous week, Avadel Pharmaceuticals had 11 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 24 mentions for Avadel Pharmaceuticals and 13 mentions for Day One Biopharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 0.55 beat Avadel Pharmaceuticals' score of -0.09 indicating that Avadel Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avadel Pharmaceuticals
4 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Day One Biopharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Avadel Pharmaceuticals has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.44, suggesting that its stock price is 244% less volatile than the S&P 500.

69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. 4.0% of Avadel Pharmaceuticals shares are owned by insiders. Comparatively, 8.4% of Day One Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Avadel Pharmaceuticals currently has a consensus price target of $24.17, suggesting a potential upside of 56.01%. Day One Biopharmaceuticals has a consensus price target of $37.67, suggesting a potential upside of 132.94%. Given Avadel Pharmaceuticals' higher probable upside, analysts clearly believe Day One Biopharmaceuticals is more favorable than Avadel Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avadel Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Day One Biopharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

Avadel Pharmaceuticals has higher revenue and earnings than Day One Biopharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Day One Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avadel Pharmaceuticals$27.96M50.18-$160.28M-$1.86-8.33
Day One BiopharmaceuticalsN/AN/A-$188.92M-$2.51-6.44

Day One Biopharmaceuticals has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -284.42%. Avadel Pharmaceuticals' return on equity of -57.28% beat Day One Biopharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Avadel Pharmaceuticals-284.42% -139.72% -79.53%
Day One Biopharmaceuticals N/A -57.28%-53.31%

Avadel Pharmaceuticals received 298 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 65.22% of users gave Avadel Pharmaceuticals an outperform vote while only 58.18% of users gave Day One Biopharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Avadel PharmaceuticalsOutperform Votes
330
65.22%
Underperform Votes
176
34.78%
Day One BiopharmaceuticalsOutperform Votes
32
58.18%
Underperform Votes
23
41.82%

Summary

Avadel Pharmaceuticals beats Day One Biopharmaceuticals on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DAWN vs. The Competition

MetricDay One BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.41B$6.74B$5.10B$7.94B
Dividend YieldN/A2.79%37.31%3.91%
P/E Ratio-6.4421.79180.1318.78
Price / SalesN/A431.692,396.36111.58
Price / CashN/A36.1836.5132.08
Price / Book4.766.115.734.68
Net Income-$188.92M$140.71M$105.22M$217.01M
7 Day Performance1.06%1.40%1.86%2.90%
1 Month Performance2.67%3.67%4.74%6.58%
1 Year Performance23.62%-1.74%7.68%10.15%

Day One Biopharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVDL
Avadel Pharmaceuticals
3.4273 of 5 stars
$16.12
-4.1%
$24.17
+49.9%
+4.6%$1.46B$27.96M-8.67154
DVAX
Dynavax Technologies
4.2359 of 5 stars
$11.00
-0.3%
$25.33
+130.3%
-0.2%$1.44B$232.28M183.33408Short Interest ↑
Analyst Revision
PCRX
Pacira BioSciences
4.8995 of 5 stars
$30.82
+1.4%
$47.40
+53.8%
-23.8%$1.43B$681.75M21.55711
MORF
Morphic
3.7857 of 5 stars
$28.36
-1.1%
$51.50
+81.6%
-48.2%$1.42B$520,000.00-8.10121News Coverage
AKRO
Akero Therapeutics
3.8717 of 5 stars
$20.30
-1.6%
$40.88
+101.4%
-57.0%$1.40BN/A-6.3455Analyst Forecast
Short Interest ↑
Analyst Revision
ANIP
ANI Pharmaceuticals
4.8711 of 5 stars
$66.03
-1.9%
$81.00
+22.7%
+38.0%$1.39B$486.82M41.27642Insider Selling
KNSA
Kiniksa Pharmaceuticals
1.7689 of 5 stars
$19.48
-0.5%
$31.00
+59.1%
+44.8%$1.38B$270.26M177.11297Short Interest ↑
GMTX
Gemini Therapeutics
0 of 5 stars
$31.84
+2.7%
N/A-6.3%$1.38BN/A-31.8431
LGND
Ligand Pharmaceuticals
4.9421 of 5 stars
$85.29
+1.5%
$116.33
+36.4%
+9.0%$1.54B$131.31M16.5058Insider Selling
News Coverage
GYRE
Gyre Therapeutics
0.7811 of 5 stars
$15.77
+0.1%
N/AN/A$1.35B$113.45M0.00593Upcoming Earnings

Related Companies and Tools

This page (NASDAQ:DAWN) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners